Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 197-203

  Kokate, Amit ^a   Li, Xiaoling ^a   Jasti, Bhaskara ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Albumin; Caco 2; Fenretinide; Protein binding; Transcellular; Transport

Indexed keywords

ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; FENRETINIDE;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG TRANSPORT; EFFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN BINDING; TRANSCYTOSIS;

ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; ELECTRIC IMPEDANCE; EXCIPIENTS; FENRETINIDE; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; POVIDONE; SERUM ALBUMIN, BOVINE; SOLUBILITY; TIME FACTORS;

EID: 34248677075     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9026-3     Document Type: Article

References (31)

1. Pollard M, Luckert PH, Sporn MB (1991) Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res 51:3610-3611
2. Formelli F, Barua AB, Olson JA (1996) Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. Faseb J 10:1014-1024
3. Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ (1998) Development of new cancer chemoprevention agents: role of pharmacokinetic/ pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 44:420-427
4. Veronesi U, De Palo G, Costa A, Formelli F, Decensi A (1996) Chemoprevention of breast cancer with fenretinide. IARC Sci Publ 87-94
5. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91:1847-1856
6. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065-1071
7. Fontana JA, Rishi AK (2002) Classical and novel retinoids: their targets in cancer therapy. Leukemia 16:463-472
8. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ (2003) Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197:185-192
9. Swanson BN, Zaharevitz DW, Sporn MB (1980) Pharmacokinetics of N-(4-Hydroxyphenyl)-all-trans-retinamide in rats. Drug Metab Dispos 8:168-172
10. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438-445
11. Law D, Krill SL, Schmitt EA, Fort JJ, Qiu Y, Wang W, Porter WR (2001) Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. J Pharm Sci 90:1015-1025
12. Lennernas H (1998) Human intestinal permeability. J Pharm Sci 87:403-410
13. Ooie T, Terasaki T, Suzuki H, Sugiyama Y (1997) Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos 25:784-789
14. Fisher JM, Wrighton SA, Calamia JC, Shen DD, Kunze KL, Thummel KE (1999) Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding. J Pharmacol Exp Ther 289:1143-1150
15. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204
16. Gan LS, Hsyu PH, Pritchard JF, Thakker D (1993) Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm Res 10:1722-1725
17. Tantishaiyakul V, Wiwattanawongsa K, Pinsuwan S, Kasiwong S, Phadoongsombut N, Kaewnopparat S, Kaewnopparat N, Rojanasakul Y (2002) Characterization of mefenamic acid-guaiacol ester: stability and transport across Caco-2 cell monolayers. Pharm Res 19:1013-1018
18. Krishna G, Chen K, Lin C, Nomeir AA (2001) Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 222:77-89
19. Saha P, Kou JH (2002) Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm 54:319-324
20. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K (2000) The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 17:1175-1180
21. Higaki K, Asai M, Suyama T, Nakayama K, Ogawara K, Kimura T (2002) Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer. Int J Pharm 239:129-141
22. He YL, Tsujimoto S, Tanimoto M, Okutani R, Murakawa K, Tashiro C (2000) Effects of protein binding on the placental transfer of propofol in the human dually perfused cotyledon in-vitro. Br J Anaesth 85:281-286
23. Pal D, Udata C, Mitra AK (2000) Transport of cosalane-a highly lipophilic novel anti-HIV agent-across caco-2 cell monolayers. J Pharm Sci 89:826-833
24. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A, Veronesi U (1993) Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2036-2042
25. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM (2000) Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21:1271-1279
26. Zanotti G, Marcello M, Malpeli G, Folli C, Sartori G, Berni R (1994) Crystallographic studies on complexes between retinoids and plasma retinol-binding protein. J Biol Chem 269:29613-29620
27. de Pee S, Dary O (2002) Biochemical indicators of vitamin A deficiency: serum retinol and serum retinol binding protein. J Nutr 132:2895S-2901S
28. Sawada GA, Ho NF, Williams LR, Barsuhn CL, Raub TJ (1994) Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning. Pharm Res 11:665-673
29. Wils P, Warnery A, Phung-Ba V, Legrain S, Scherman D (1994) High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther 269:654-658
30. Rubas W, Cromwell M (1997) The effect of chemical modifications on octanol/water partition (log D) and permeabilities across Caco-2 monolayers. Adv Drug Deliv Rev 23:157-162
31. Sawada GA, Barsuhn CL, Lutzke BS, Houghton ME, Padbury GE, Ho NF, Raub TJ (1999) Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J Pharmacol Exp Ther 288:1317-1326